Depomed (DEPO) Misses Q4 EPS by 13c

Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.16, $0.13 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $110.24 million.

Non-GAAP adjusted earnings includes a reduction of $10 million, or $0.13 cents per share related to the tax treatment of the cebranopadol transaction.

For earnings history and earnings-related data on Depomed (DEPO) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Victory Capital reports $346.1 billion in total client assets for June
• Chesapeake Utilities plans $1.2B Florida gas pipeline project